Cargando…
Preintervention MCP-1 serum levels as an early predictive marker of tumor response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
BACKGROUND: Transarterial chemoembolization (TACE) is a widely accepted treatment for unresectable or intermediate-stage hepatocellular carcinoma (HCC). However, response rates to TACE are heterogeneous and it is not fully understood which patients benefit most from TACE therapy in terms of tumor re...
Autores principales: | You, Ran, Jiang, Hao, Xu, Qingyu, Yin, Guowen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797576/ https://www.ncbi.nlm.nih.gov/pubmed/35116424 http://dx.doi.org/10.21037/tcr-20-2791 |
Ejemplares similares
-
Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma
por: Song, Myeong Jun, et al.
Publicado: (2016) -
Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Ho, Shu-Yein, et al.
Publicado: (2017) -
Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
por: Rebonato, A., et al.
Publicado: (2017) -
Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
por: You, Ran, et al.
Publicado: (2022) -
Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization
por: Ventura, Yossi, et al.
Publicado: (2018)